Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.56 USD
Change Today -0.11 / -1.27%
Volume 249.7K
CCXI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (CCXI) Snapshot

Open
$8.74
Previous Close
$8.67
Day High
$9.00
Day Low
$8.43
52 Week High
01/29/15 - $9.20
52 Week Low
12/5/14 - $4.06
Market Cap
374.0M
Average Volume 10 Days
173.9K
EPS TTM
$-1.09
Shares Outstanding
43.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHEMOCENTRYX INC (CCXI)

Related News

No related news articles were found.

chemocentryx inc (CCXI) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (CCXI) Details

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates in clinical development include CCX140 that has completed a Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; CCX872, an orally administered inhibitor that is under Phase Ib clinical trial for pancreatic cancer; and CCX168, which has completed a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic anti-body associated renal vasculitis. The company’s drug candidates in clinical development also comprise Vercirnon for the treatment of patients with moderate-to-severe Crohn’s disease; and CCX507 inhibitor, which has completed a Phase I clinical trial for the treatment of inflammatory bowel disease. Its earlier-stage programs in immuno-oncology and autoimmune diseases include CCR6 Inhibitor for autoimmune diseases; CCR4 Inhibitor for atopic autoimmune disorders; CXCR6 Inhibitor for liver diseases; CCR1 Inhibitor for inflammatory diseases and rheumatoid arthritis; and CXCR7 Inhibitor for glioblastoma multiforme. The company was founded in 1997 and is headquartered in Mountain View, California.

58 Employees
Last Reported Date: 03/13/15
Founded in 1997

chemocentryx inc (CCXI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $550.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $400.0K
Chief Medical Officer
Total Annual Compensation: $384.3K
Compensation as of Fiscal Year 2014.

chemocentryx inc (CCXI) Key Developments

ChemoCentryx, Inc. Announces Positive Results from Chemocentryx Phase II Diabetic Nephropathy Trial with Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At the 52nd ERA-EDTA Congress

ChemoCentryx, Inc. announced data presentations from two of its chemoattractant receptor programs, CCR2 and C5aR, at the 52ndEuropean Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress being held May 28 to 31 in London, UK. In a Late Breaking Clinical Trial presentation, positive 52-week data from the Company's Phase II clinical trial in patients with diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2, were presented by Professor Dick de Zeeuw, M.D., Ph.D., Chair of the Research Section of the Department of Clinical Pharmacy and Pharmacology at the University Medical Center in Groningen, The Netherlands. Professor de Zeeuw's oral presentation focused on the CCX140 Phase II study and its primary endpoint. As previously announced, top line data from the CCX140 Phase II trial in patients with diabetic nephropathy included the following results: the trial met its primary endpoint by demonstrating that treatment with 5 mg of CCX140 given orally once daily added to a standard of care regimen (SOC) of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor II blocker (ARB) treatment resulted in a statistically significant (p=0.0148) reduction in urinary albumin:creatinine ratio (UACR), beyond that achieved with SOC alone; the maximum treatment effect was reached at 12 weeks; in patients who received 5 mg CCX140 continuously for 52 weeks, a sustained reduction in albuminuria induced by CCX140 relative to SOC alone was observed over the full year; treatment with CCX140 showed improvements in the profile of the estimated glomerular filtration rate (eGFR), represented by an attenuation in the slope of annual decline in eGFR. The treatment group receiving 5 mg of CCX140 in addition to SOC showed an attenuated annual slope decline of 1.9 mL/min/1.73 m2, compared to SOC alone group, 3.4 mL/min/1.73 m2. These results represent a 44% annualized improvement in eGFR over SOC alone; in a pre-specified sub-population in the study, patients who were highly proteinuric (baseline albuminuria levels of 800mg/g creatinine and above), a 66% annualized relative improvement in eGFR slope over SOC alone was observed; CCX140 appeared to be well tolerated with a low overall dropout rate over the 52-week treatment period. Regarding another chemoattractant receptor inhibitor program at the Company, ChemoCentryx scientists and their collaborators will outline research in atypical Hemolytic Uremic Syndrome (aHUS) and the ability of CCX168, a C5aR inhibitor, to significantly reduce the formation of platelet micro-thrombi on an ex-vivo assay system of endothelial cells. These data will be presented in a poster session on Saturday, May 30th. The inhibition of micro-thrombi was dose-dependent on CCX168 and, in side-by-side experiments, the anti-thrombotic effect of CCX168 were comparable to that of eculizumab, which is the first agent approved for aHUS. The Company is initiating a CCX168 Phase IIa proof-of-concept study in aHUS patients with end stage renal disease.

ChemoCentryx, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ChemoCentryx, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations was $12,109,000 against $11,672,000 a year ago. Net loss was $12,006,000 against $11,537,000 a year ago. Basic and diluted net loss per share was $0.28 against $0.27 a year ago.

ChemoCentryx, Inc. to Report Q1, 2015 Results on May 06, 2015

ChemoCentryx, Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCXI:US $8.56 USD -0.11

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CCXI.
View Industry Companies
 

Industry Analysis

CCXI

Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit www.chemocentryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.